CoChat

Treatment of Tics and Tourette Syndrome

Singer, Harvey S. · 2010 · Current Treatment Options in Neurology
Cited by 97

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11940-010-0095-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 78

  1. Singer HS: Tourette’s syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149–159. · DOI · Paper page
  2. Walkup JT, Ferrao Y, Leckman JF, et al.: Tic disorders: some key issues for DSM-V. Depress Anxiety 2010, 27:600–610. · DOI · Paper page
  3. Kurlan R, Como PG, Miller B, et al.: The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 59:414–420. · DOI · Paper page
  4. Cavanna AE, Eddy C, Rickards HE: Cognitive functioning in Tourette syndrome. Discov Med 2009, 8:191–195.
  5. Pringsheim T, Lang A, Kurlan R, et al.: Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468–472. · DOI
  6. Mejia NI, Jankovic J: Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11–17. · DOI
  7. Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136–142. · DOI · Paper page
  8. O’Connor KP, Laverdure A, Taillon A, et al.: Cognitive behavioral management of Tourette’s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther 2009, 47:1090–1095. · DOI
  9. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008.
  10. Himle MB, Woods DW, Piacentini JC, Walkup JT: Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719–725. · DOI · Paper page
  11. Garcia-Lopez R, Romero-Gonzalez J, Perea-Milla E, et al.: [An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children.]. Med Clin (Barc) 2008, 131:689–692. · doi:10.1157/13129113
  12. Ma S, Liu XY, Yu RL, Chen LJ: [Clinical observation on acupuncture for treatment of Tourette’s syndrome]. Zhongguo Zhen Jiu 2006, 26:392–394.
  13. Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol 2006, 9:95–100. · DOI · Paper page
  14. Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314–2315. · DOI
  15. Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420–425. · DOI · Paper page
  16. Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330–336. · DOI · Paper page
  17. Du YS, Li HF, Vance A, et al.: Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 2008, 42:807–813. · DOI · Paper page
  18. Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067–1074. · DOI · Paper page
  19. Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325–332. · DOI · Paper page
  20. Abuzzahab FS, Brown VL: Control of Tourette’s syndrome with topiramate. Am J Psychiatry 2001, 158:968. · DOI
  21. Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32–34. · DOI
  22. Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2009, 81:70–73. · DOI · Paper page
  23. Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005, 20:714–718. · DOI · Paper page
  24. Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541–545. · DOI
  25. Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764–1770. · DOI · Paper page
  26. Shapiro AK: Gilles de la Tourette Syndrome. New York: Raven; 1988.
  27. Awaad Y: Tics in Tourette syndrome: new treatment options. J Child Neurol 1999, 14:316–319. · DOI · Paper page
  28. Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599–604. · DOI · Paper page
  29. Drtilkova I, Balaotkova B, Lemanova H, Zak J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296.
  30. Schneeweiss S, Avorn J: Antipsychotic agents and sudden cardiac death—How should we manage the risk? N Engl J Med 2009, 360:294–296. · DOI · Paper page
  31. Pringsheim T, Marras C: Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009, CD006996. This comprehensive review of prior studies assessed the benefits and risks of pimozide in comparison to placebo or other medications in treating tics in Tourette syndrome. · DOI · Paper page
  32. Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71–74. · DOI · Paper page
  33. Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271–272. · DOI · Paper page
  34. Jankovic J: Treatment of hyperkinetic movement disorders. Lancet Neurol 2009, 8:844–856. · DOI · Paper page
  35. Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989, 46:722–730. · DOI · Paper page
  36. Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31–39. · DOI · Paper page
  37. Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50–56. · DOI · Paper page
  38. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004, 43:206–214. · DOI
  39. Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509–515. · DOI · Paper page
  40. Kawohl W, Schneider F, Vernaleken I, Neuner I: Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009, 21:224. · doi:10.1176/appi.neuropsych.21.2.224
  41. Murphy TK, Mutch PJ, Reid JM, et al.: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009, 19:441–447. · DOI · Paper page
  42. Davies L, Stern JS, Agrawal N, Robertson MM: A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006, 21:447–453. · DOI
  43. Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197–205. · DOI
  44. Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292–299. · DOI · Paper page
  45. Willmund G, Lee AH, Wertenauer F, et al.: Vocal tics associated with ziprasidone. J Clin Psychopharmacol 2009, 29:611–612. · doi:10.1097/jcp.0b013e3181c06dad
  46. Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001, 62:290–294. · DOI · Paper page
  47. McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501–508. · DOI · Paper page
  48. Onofrj M, Paci C, D’Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443–446. · DOI
  49. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003, 13:295–299. · DOI · Paper page
  50. Copur M, Arpaci B, Demir T, Narin H: Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: a retrospective case-note survey. Clin Drug Investig 2007, 27:123–130. · DOI
  51. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193–197. · DOI · Paper page
  52. Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord 2007, 22:10–13. · DOI
  53. Porta M, Sassi M, Cavallazzi M, et al.: Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008, 28:443–459. · DOI
  54. Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699–1706. · DOI · Paper page
  55. Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605–610. · DOI · Paper page
  56. Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193. · DOI · Paper page
  57. Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010, 16:478–481. · DOI
  58. Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420–423. · DOI
  59. Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229–235. · DOI · Paper page
  60. Ho CS, Chen HJ, Chiu NC, et al.: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009, 108:788–793. · DOI
  61. Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223–229. · DOI
  62. Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862–867. · DOI
  63. Cubo E, Fernandez Jaen A, Moreno C, et al.: Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008, 30:182–189. · DOI
  64. Bortolato M, Muroni A, Marrosu F: Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry 2007, 164:1914–1915. · DOI
  65. Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:324–331. · DOI · Paper page
  66. Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999, 156:1122–1123. · DOI
  67. Hoekstra PJ, Minderaa RB, Kallenberg CG: Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004, 65:537–542. · DOI · Paper page
  68. Neimat JS, Patil PG, Lozano AM: Novel surgical therapies for Tourette syndrome. J Child Neurol 2006, 21:715–718. · DOI
  69. Porta M, Sassi M, Ali F, et al.: Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009, 67:585–590. · DOI
  70. Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76.
  71. Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76. · DOI · Paper page
  72. Shields DC, Cheng ML, Flaherty AW, et al.: Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 2008, 86:87–91. · DOI
  73. Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 2004, 19:3–14. · DOI · Paper page
  74. Erenberg G: The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol 2005, 12:217–221. · DOI
  75. Singer HS, Brown J, Quaskey S, et al.: The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74–81. · DOI · Paper page
  76. Spencer T, Biederman J, Coffey B, et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649–656. · DOI · Paper page
  77. Storch EA, Bjorgvinsson T, Riemann B, et al.: Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin 2010, 74:167–185. · DOI · Paper page
  78. Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010, 6:233–242. · DOI

Cited by

See all 97

Metadata

Authors
Singer, H. S.
Venue
Current Treatment Options in Neurology
Published
2010-09-10
Volume
12
Issue
6
Pages
539-561
ISSN
  • 1092-8480
  • 1534-3138
Cited by
97
References
13
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.